ES2059592T3 - Esteres de acidos carbamicos de 7-hidroxi-2,3,4,5-tetrahidro-1h-3-benzazepinas sustituidas. - Google Patents

Esteres de acidos carbamicos de 7-hidroxi-2,3,4,5-tetrahidro-1h-3-benzazepinas sustituidas.

Info

Publication number
ES2059592T3
ES2059592T3 ES89103531T ES89103531T ES2059592T3 ES 2059592 T3 ES2059592 T3 ES 2059592T3 ES 89103531 T ES89103531 T ES 89103531T ES 89103531 T ES89103531 T ES 89103531T ES 2059592 T3 ES2059592 T3 ES 2059592T3
Authority
ES
Spain
Prior art keywords
alkyl
benzazepine
tetrahydro
hydroxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89103531T
Other languages
English (en)
Inventor
Kristian Tage Hansen
Hans Bundgaard
Peter Faarup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2059592T3 publication Critical patent/ES2059592T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS DE FORMULA(I), EN LA QUE R1 ES H, HALOGENO O UN GRUPO ALQUILO DE 1 A 4 C; R2 ES HALOGENO, CF3 O CN; R5 ES FURILO, TIENILO, PIRIDILO O VARIOS SISTEMAS DE ANILLOS QUE SE ESPECIFICAN; R6 ES H O CH3; R7 ES H O ALQUILO DE 1 A 4 C; R8 ES H, ALQUILO, ARALQUILO, CICLOALQUILO O ARILO; R9 ES H O JUNTO CON R8 FORMA UN ANILLO PIPERIDINO, PIRROHIDINILO, MORFOLINO O PIPERAZINO O R9 ES ALQUILO O ALCOXICARBONILO DE FORMULA CR11 - CO - OR13 (SIENDO R11 H, CH3, (CH3)CH, CH2CH(CH3)2, - CH(CH3) - CH2 - CH3, - CH2 - CH2 - S - CH33, O EL GRUPO (II); Y R13 ES H, ALQUILO, CICLOALQUILO, ARALQUILO O UN GRUPO 2 - ACETAMIDO CON DIVERSAS OPCIONES). LA INVENCION SE REFIERE TAMBIEN A LAS SALES DE DICHOS COMPUESTOS ACEPTABLES PARA USO FARMACEUTICO. LOS COMPUESTOS SON UTILES COMO FARMACOS CON ACTIVIDAD PARA EL TRATAMIENTO DE ALTERACIONES MENTALES.
ES89103531T 1988-03-01 1989-02-28 Esteres de acidos carbamicos de 7-hidroxi-2,3,4,5-tetrahidro-1h-3-benzazepinas sustituidas. Expired - Lifetime ES2059592T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK107688A DK107688D0 (da) 1988-03-01 1988-03-01 Carbaminsyreestere af substituerede 7-hydroxy-2,3,4,5-tetrahydro-1h-3-benzazepiner

Publications (1)

Publication Number Publication Date
ES2059592T3 true ES2059592T3 (es) 1994-11-16

Family

ID=8100728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89103531T Expired - Lifetime ES2059592T3 (es) 1988-03-01 1989-02-28 Esteres de acidos carbamicos de 7-hidroxi-2,3,4,5-tetrahidro-1h-3-benzazepinas sustituidas.

Country Status (18)

Country Link
US (1) US5017571A (es)
EP (1) EP0331130B1 (es)
JP (1) JPH01254679A (es)
KR (1) KR0126473B1 (es)
AT (1) ATE95179T1 (es)
AU (1) AU613716B2 (es)
CA (1) CA1312863C (es)
DE (1) DE68909448T2 (es)
DK (1) DK107688D0 (es)
ES (1) ES2059592T3 (es)
FI (1) FI94955C (es)
IE (1) IE64247B1 (es)
IL (1) IL89207A0 (es)
NO (1) NO173825C (es)
NZ (1) NZ228151A (es)
PH (1) PH26368A (es)
PT (1) PT89887B (es)
ZA (1) ZA891537B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK67489D0 (da) * 1989-02-14 1989-02-14 Novo Industri As Nye benzazepinderivater
ES2190428T3 (es) * 1991-06-28 2003-08-01 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogeno.
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5470850A (en) * 1992-02-24 1995-11-28 Novo Nordisk A/S 2,3,4,5-tetrahydro-1H-3-benzazepines
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US6458784B1 (en) 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US20030125317A1 (en) * 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
AU2004253888B2 (en) 2003-06-17 2010-11-11 Arena Pharmaceuticals, Inc. Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases
WO2005042491A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
SI1833473T1 (sl) 2004-12-23 2010-01-29 Arena Pharm Inc Sestavki modulatorjev 5HT2C receptorjev in postopki uporabe
JP5491421B2 (ja) 2008-03-04 2014-05-14 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス
KR20130112848A (ko) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
CA2808890A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
JP6272695B2 (ja) 2010-09-01 2018-01-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形
WO2012030938A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
SG188361A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
JP2015534563A (ja) 2012-10-09 2015-12-03 アリーナ ファーマシューティカルズ， インコーポレイテッド 体重管理の方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3393192A (en) * 1965-04-26 1968-07-16 Schering Corp Novel benzazepines
US3609138A (en) * 1967-12-22 1971-09-28 Ciba Geigy Corp 1-aryl-3-benzazepines
US4011319A (en) * 1975-07-02 1977-03-08 Smithkline Corporation Pharmaceutical compositions and methods involving benzazepine derivatives
ZA792043B (en) * 1978-05-08 1980-05-28 Scherico Ltd Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepines,process for the preparation thereof and pharmaceutical compositions containing them
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
DK180485D0 (da) * 1985-04-22 1985-04-23 Novo Industri As Nitrogenholdige forbindelser
PH27337A (en) * 1987-03-27 1993-06-08 Schering Corp Substituted benzazepines their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JPH01254679A (ja) 1989-10-11
KR0126473B1 (ko) 1997-12-24
FI94955C (fi) 1995-11-27
PT89887B (pt) 1994-05-31
FI890841A0 (fi) 1989-02-22
IL89207A0 (en) 1989-09-10
NO890857L (no) 1989-09-04
NO890857D0 (no) 1989-02-28
CA1312863C (en) 1993-01-19
NZ228151A (en) 1991-08-27
FI890841A7 (fi) 1989-09-02
KR890014494A (ko) 1989-10-24
AU613716B2 (en) 1991-08-08
EP0331130B1 (en) 1993-09-29
NO173825C (no) 1994-02-09
FI94955B (fi) 1995-08-15
DK107688D0 (da) 1988-03-01
AU3090789A (en) 1989-09-07
IE890420L (en) 1989-09-01
US5017571A (en) 1991-05-21
IE64247B1 (en) 1995-07-26
DE68909448D1 (de) 1993-11-04
EP0331130A1 (en) 1989-09-06
PH26368A (en) 1992-06-01
ATE95179T1 (de) 1993-10-15
ZA891537B (en) 1989-11-29
NO173825B (no) 1993-11-01
DE68909448T2 (de) 1994-02-10
PT89887A (pt) 1989-11-10

Similar Documents

Publication Publication Date Title
ES2059592T3 (es) Esteres de acidos carbamicos de 7-hidroxi-2,3,4,5-tetrahidro-1h-3-benzazepinas sustituidas.
ES2124707T3 (es) Compuestos heterociclicos y su preparacion y utilizacion.
MX9300031A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene.
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
GB1069343A (en) Propanolamine derivatives
ES2053451T3 (es) Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
AR009052A1 (es) Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
ES2119124T3 (es) Bencimidazoles utiles para el tratamiento de trastornos del sistema nervioso.
AR043700A1 (es) Derivados de 3-substituida-4-pirimidona
AR020165A1 (es) Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos
ES2051772T3 (es) 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos.
ES2087097T3 (es) Derivados de acidos fenilcarboxilicos que contienen un heterociclo.
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
AR034249A1 (es) Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones
AR019167A1 (es) Derivados heteroaromaticos de piperazinas di-n-sustituidas y piperidinas 1,4-disustituidas, composiciones farmaceuticas y el uso de los mismos para lapreparacion de medicamentos
ES2071666T3 (es) Derivados de pirazoloisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2004409A6 (es) Procedimiento parala preparacion de nuevos derivados piperazinas 1,4-disustituidos
ES8609193A1 (es) Procedimiento para preparar analogos de mevalonolactona y derivados de los mismos
AR016973A1 (es) Uso de aminometil-cromanos sustituidos para la produccion de un medicamento util para el tratamiento de enfermedades neurodegenerativas y para el estimulode la regeneracion neuronal
ES2102043T3 (es) Derivados de 22-en-25-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que los contienen, asi como su utilizacion en calidad de medicamentos.
ES2090024T3 (es) Compuestos de cefemo y procedimientos para su preparacion.
AR046874A1 (es) Nuevos metodos
AR039391A1 (es) Compuesto de ciclopenteno, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 331130

Country of ref document: ES